Prostate Cancer - Results from #1660

Incidental prostate cancer diagnosis is common after holmium laser enucleation of the prostate. December 11, 2023

Evaluation of the Reliability and the Performance of Magnetic Resonance Imaging Radiomics in the Presence of Randomly Generated Irrelevant Features for Prostate Cancer. December 11, 2023

Comparative Analysis of Morphological and Functional Effects of 225Ac- and 177Lu-PSMA Radioligand Therapies (RLTs) on Salivary Glands. December 11, 2023

Liquid Biopsies for Early Response Evaluation of Radium-223 in Metastatic Prostate Cancer. December 11, 2023

Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [68Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Ma December 11, 2023

VALIDATION OF METASTASIS-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN LOCALIZED PROSTATE CANCER IN THE ERA OF DOCETAXEL FOR CASTRATION RESISTANT PROSTATE CANCER. December 11, 2023

Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. December 11, 2023

Dosimetric predictors for genitourinary toxicity in MR-guided stereotactic body radiation therapy (SBRT): Substructure with fraction-wise analysis. December 8, 2023

The Impact of Delayed Radical Prostatectomy on Recurrence Outcomes After Initial Active Surveillance: Results from a Large Institutional Cohort. December 8, 2023

Illustration of association between change in prostate-specific antigen (PSA) values and time to tumor status after treatment for prostate cancer patients: a joint modelling approach. December 8, 2023

Cost Effectiveness of Systemic Treatment Intensification for Metastatic Hormone-sensitive Prostate Cancer: Is Triplet Therapy Cost Effective? December 8, 2023

Prostate volume variation during 1.5T MR-guided adaptive stereotactic body radiotherapy (SBRT) and correlation with treatment toxicity. December 8, 2023

Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database. December 7, 2023

Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy. December 7, 2023

Comparison of Multiple Segmentation Methods for Volumetric Delineation of Primary Prostate Cancer with Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL PET/CT. December 7, 2023

Association of PSMA PET-derived Parameters and Outcomes of Patients Treated for Oligorecurrent Prostate Cancer. December 7, 2023

Patient and physician perspectives on treatments for low-risk prostate cancer: a qualitative study. December 7, 2023

Activation of Dendritic Cells Isolated from the Blood of Patients with Prostate Cancer by Ex Vivo Fluid Shear Stress Stimulation. December 6, 2023

Long-Term Impact of Medicaid Expansion on Prostate Cancer Screening. December 6, 2023

Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study. December 6, 2023

Page 84 of 1435